MORE►
MedCognetics
[Image: Myvector/iStockphoto]
Dallas’ MedCognetics Gets $750K NIH Grant to Research Unbiased AI for Breast Cancer Detection
by David Seeley | Jan 26, 2023
Last month, we told you about MedCognetics getting FDA clearance for its unbiased AI-enabled software for breast cancer screening. Today, the Dallas-based company announced it has been awarded $750,000 from an NIH program to research unbiased AI for breast cancer detection.
The NIH's AIM-AHEAD program—short for Artificial Intelligence/Machine Learning Consortium to Advance Health Equity and Researcher Diversity—awarded the grant. "This NIH grant will play an important role in future product development as well as helping us further expand our global market penetration," said MedCognetics CEO Debasish Nag.
by David Seeley |
Dec 20, 2022
The early-stage startup's QmTRIAGE software platform uses AI and machine learning to detect early breast cancers with a "high rate" of accuracy, MedCognetics says. The company has worked with UT Southwestern and UT Dallas to ensure its AI improves outcomes for "all ethnicities," at a time when racial disparities in AI have become a growing concern.
MORE►
